Next Post

AbbVie and biotech Cugene Announce Partnership for Research in Autoimmune Diseases

AbbVie and Cugene Inc., a biotechnology company focused on developing innovative high-tech drugs in oncology and immunology for autoimmune diseases and cancer, announced a worldwide and exclusive agreement for the licensing of CUG252, a selective IL-2 T Regulatory mutein, as well as other IL-2 muteins, for the treatment of autoimmune […]